ALGS – aligos therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Form EFFECT Aligos Therapeutics,
Form SC 13G/A Aligos Therapeutics, Filed by: Vivo Capital Fund VIII, L.P.
Form SC 13G/A Aligos Therapeutics, Filed by: EcoR1 Capital, LLC
Form SC 13G/A Aligos Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Form SC 13G/A Aligos Therapeutics, Filed by: Alyeska Investment Group, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.